Rajeev Venkayya is President of the Global Vaccine Business Unit at Takeda Pharmaceutical Company Ltd. He leads a vertically-integrated business developing vaccines for dengue, norovirus and Zika. Dr. Venkayya serves as an independent member of the board of the Coalition for Epidemic Preparedness Innovations (CEPI) and the International AIDS Vaccine Initiative (IAVI) and is a life member of the Council on Foreign Relations.
Prior to joining Takeda, Dr. Venkayya served as Director of Vaccine Delivery at the Bill & Melinda Gates Foundation’s Global Health Program and served on the board of Gavi, the Vaccine Alliance. Before that, he was the Special Assistant to the President for Biodefense at the White House. In this capacity, he oversaw U.S. preparedness for bioterrorism and biological threats and was responsible for the development and implementation of the National Strategy for Pandemic Influenza.
Dr. Venkayya trained in Pulmonary & Critical Care Medicine at the University of California, San Francisco, where he also served on the faculty. He was a resident and Chief Medical Resident in internal medicine at the University of Michigan. He received his B.S./M.D. from the Northeast Ohio Universities College of Medicine, where he was inducted into the Alpha Omega Alpha honorary medical society.
Dr. Venkayya lives in Boston with his wife Viktoria and their two sons.